Ivana Horvat1, Ana Boban2, Renata Zadro3, Margareta Radic Antolic4, Ranka Serventi-Seiwerth5, Pavle Roncevic5, Ivo Radman5, Dubravka Sertic5, Marijo Vodanovic5, Drazen Pulanic2, Sandra Basic-Kinda5, Nadira Durakovic2, Silva Zupancic-Salek6, Radovan Vrhovac2, Igor Aurer2, Damir Nemet7, Boris Labar8. 1. Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia. Electronic address: ivanahorvat13@gmail.com. 2. Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. 3. Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia; Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia. 4. Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia. 5. Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia. 6. Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Osijek, Osijek, Croatia. 7. School of Medicine, University of Zagreb, Zagreb, Croatia; International University Libertas, Zagreb, Croatia. 8. School of Medicine, University of Zagreb, Zagreb, Croatia; Center for Medical Experts, Zagreb, Croatia.
Abstract
INTRODUCTION: Thrombosis is the most common complication in Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms patients. PATIENTS AND METHODS: In a cohort of 258 Ph- myeloproliferative neoplasm patients, the difference between patients with and without thrombosis was analyzed according to genetic thrombophilia factors, JAK2 V617F status and burden allele, blood count, cardiovascular risk factors and age. Patients were also divided in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) subgroups as well as by the type of thrombosis. RESULTS: Analysis of cardiovascular risk factors regarding arterial thrombosis showed that PV patients with thrombosis had higher incidence of diabetes (P = .030), ET patients more often had hypertension (P = .003) and hyperlipidemia (P = .005), while PMF patients had hyperlipidemia (P = .046) and at least one cardiovascular risk factor (P = .044). Moreover, leukocytes > 18 × 109/L and V617F burden allele > 25.7% were statistically significantly different in PV patients (P = .019 and borderline significant at P = .055, respectively), while in ET patients leukocytes > 9.2 × 109/L (P < .001) and age at diagnosis of > 55 years were statistically significantly different (P = .002). PMF patients with V617F burden allele ≤ 34.8% were more prone to thrombosis (P = .032). When comparing patients with and without venous thrombosis, cutoff value of V617F burden allele > 90.4% was significant for PV patients with thrombosis (P = .036), as was > 56.7% for PMF patients with thrombosis (P = .046). Platelets ≤ 536 × 109/L and age at diagnosis > 54 years showed statistically significant difference for ET patients with thrombosis (P = .015 and P = .041, respectively). CONCLUSION: On the basis of our results, a new scoring system for thrombosis risk in PV could be made, while PMF prognostic model may be expanded for better recognition of potential thrombotic risk factors.
INTRODUCTION:Thrombosis is the most common complication in Philadelphia chromosome negative (Ph-) myeloproliferative neoplasmspatients. PATIENTS AND METHODS: In a cohort of 258 Ph- myeloproliferative neoplasmpatients, the difference between patients with and without thrombosis was analyzed according to genetic thrombophilia factors, JAK2 V617F status and burden allele, blood count, cardiovascular risk factors and age. Patients were also divided in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) subgroups as well as by the type of thrombosis. RESULTS: Analysis of cardiovascular risk factors regarding arterial thrombosis showed that PV patients with thrombosis had higher incidence of diabetes (P = .030), ET patients more often had hypertension (P = .003) and hyperlipidemia (P = .005), while PMF patients had hyperlipidemia (P = .046) and at least one cardiovascular risk factor (P = .044). Moreover, leukocytes > 18 × 109/L and V617F burden allele > 25.7% were statistically significantly different in PV patients (P = .019 and borderline significant at P = .055, respectively), while in ET patients leukocytes > 9.2 × 109/L (P < .001) and age at diagnosis of > 55 years were statistically significantly different (P = .002). PMF patients with V617F burden allele ≤ 34.8% were more prone to thrombosis (P = .032). When comparing patients with and without venous thrombosis, cutoff value of V617F burden allele > 90.4% was significant for PV patients with thrombosis (P = .036), as was > 56.7% for PMF patients with thrombosis (P = .046). Platelets ≤ 536 × 109/L and age at diagnosis > 54 years showed statistically significant difference for ET patients with thrombosis (P = .015 and P = .041, respectively). CONCLUSION: On the basis of our results, a new scoring system for thrombosis risk in PV could be made, while PMF prognostic model may be expanded for better recognition of potential thrombotic risk factors.
Authors: Mohammed Sabry El-Ghonemy; Shaimaa El-Ashwah; May Denewer; Eman Adel Soliman; Mohammed El-Baiomy; Heidi Elkerdawy; Ahmed El-Sebaie Journal: Asian Pac J Cancer Prev Date: 2021-04-01
Authors: Mohamed S El-Ghonemy; Solafa El Sharawy; Maryan Waheeb Fahmi; Shaimaa El-Ashwah; May Denewer; M A El-Baiomy Journal: Adv Hematol Date: 2020-03-30